Craig-Hallum analyst Alexander Nowak maintained a Buy rating on DermTech (DMTK – Research Report) today. The company’s shares closed last Friday at $3.23.
According to TipRanks, Nowak is a 3-star analyst with an average return of 3.4% and a 45.00% success rate. Nowak covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, REPRO-MED Systems, and Exact Sciences.
DermTech has an analyst consensus of Strong Buy, with a price target consensus of $6.00.
See the top stocks recommended by analysts >>
Based on DermTech’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.48 million and a GAAP net loss of $31.27 million. In comparison, last year the company earned a revenue of $3.72 million and had a GAAP net loss of $30.11 million
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DMTK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company is headquartered in La Jolla, CA.
Read More on DMTK:
